Beneficial vascular and metabolic effects of peroxisome proliferator-activated receptor-α activators

被引:101
作者
Han, SH
Quon, MJ
Koh, KK
机构
[1] Gil Heart Ctr, Div Cardiol, Gachon Med Sch, Inchon 405760, South Korea
[2] NIH, Diabet Unit, Clin Invest Lab, NCCAM, Bethesda, MD 20892 USA
关键词
fibrates; endothelium; adipose tissue; insulin resistance; cardiovascular diseases;
D O I
10.1161/01.HYP.0000187900.36455.4c
中图分类号
R6 [外科学];
学科分类号
1002 [临床医学]; 100210 [外科学];
摘要
Fibric acid is a synthetic ligand of the nuclear receptor peroxisome proliferator-activated receptor (PPAR)-alpha that is highly expressed in skeletal muscle and heart, where it promotes beta-oxidation of fatty acids to mediate hypolipidemic actions. PPAR-alpha regulates expression of key proteins involved in atherogenesis, vascular inflammation, plaque instability, and thrombosis. Thus, PPAR-alpha may exert direct antiatherogenic actions in the vascular wall. Endothelial dysfunction associated with the metabolic syndrome and other insulin-resistant states is characterized by impaired insulin-stimulated nitric oxide production from the endothelium and decreased blood flow to skeletal muscle. Thus, improvement in insulin sensitivity leads to improved endothelial function. This may be an additional mechanism whereby fibrates decrease the incidence of coronary heart disease. Adiponectin is a protein secreted specifically by adipose cells that may couple regulation of insulin sensitivity with energy metabolism and serve to link obesity with insulin resistance. In this review, we discuss the mechanisms underlying the vascular and metabolic effects of fibrates that may act synergistically to prevent or regress atherosclerosis and coronary heart disease.
引用
收藏
页码:1086 / 1092
页数:7
相关论文
共 66 条
[1]
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl [J].
Andrews, TC ;
Whitney, EJ ;
Green, G ;
Kalenian, R ;
Personius, BE .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (07) :831-835
[2]
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia [J].
Athyros, VG ;
Papageorgiou, AA ;
Athyrou, VV ;
Demitriadis, DS ;
Kontopoulos, AG .
DIABETES CARE, 2002, 25 (07) :1198-1202
[3]
Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis [J].
Barbier, O ;
Torra, IP ;
Duguay, Y ;
Blanquart, C ;
Fruchart, JC ;
Glineur, C ;
Staels, B .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (05) :717-726
[4]
Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives [J].
Chapman, MJ .
ATHEROSCLEROSIS, 2003, 171 (01) :1-13
[5]
Adiponectin stimulates production of nitric oxide in vascular endothelial cells [J].
Chen, H ;
Montagnani, M ;
Funahashi, T ;
Shimomura, I ;
Quon, MJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (45) :45021-45026
[6]
Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARα, PPARγ, and LXR [J].
Chinetti, G ;
Zawadski, C ;
Fruchart, JC ;
Staels, B .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 314 (01) :151-158
[7]
Colville-Nash PR, 1998, J IMMUNOL, V161, P978
[8]
Deplanque D, 2003, J NEUROSCI, V23, P6264
[9]
The benefit of fibrates in the treatment of 'bad HDL-C responders to statins' [J].
Devroey, D ;
Velkeniers, B ;
Duquet, W ;
Betz, W .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 101 (02) :231-235
[10]
PPARα activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats [J].
Diep, QN ;
Benkirane, K ;
Amiri, F ;
Cohn, JS ;
Endemann, D ;
Schiffrin, EL .
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2004, 36 (02) :295-304